Dodge & Cox, JPMorgan Chase & Co. and others have reduced their position in Novartis AG, while many others like CW Advisors LLC, Lido Advisors LLC and Legal & General Group Plc, have increased their stakes. Novartis's shares have been on an upswing, with a 17.5% rise challenge-valuating the stock's attractiveness. Morgan Stanley offered an upgrade following a stock pullback and the launch of Rhapsido, shown strength in the market, despite some wavering due to generic competition. Novartis has also acquired Regulus Therapeutics and Avidity Biosciences for about $12 billion in cash, with a promising growth path projected through 2029 by TD Cowen. However, the pharmaceutical titan met financial turbulence due to a major sales miss of its primary moneymaker. Furthermore, Goldman Sachs issued a 'Sell' rating considering the stock's overvaluation. Yet, Novartis continues to be a top value and momentum stock, backed by the FDA approving its SMA gene replacement.
Novartis Stocks News Analytics from Wed, 25 Jun 2025 07:00:00 GMT to Fri, 05 Dec 2025 14:03:31 GMT -
Rating 5
- Innovation -2
- Information 8
- Rumor 3
